Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 104

Results For "NSE"

2392 News Found

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
Clinical Trials | February 28, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis


NIA signs MoU with Department of Thai Traditional and Alternative Medicine
Policy | February 28, 2024

NIA signs MoU with Department of Thai Traditional and Alternative Medicine

MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine


Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility
Drug Approval | February 26, 2024

Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility

The observations do not pose any risk to site's compliance standards or its business continuity


India implementing largest digital programme for TB surveillance
News | February 24, 2024

India implementing largest digital programme for TB surveillance

Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi


Orchid Pharma's 'Exblifep' receives USFDA approval
Drug Approval | February 24, 2024

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis
Drug Approval | February 20, 2024

European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis

VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU


Biocon included in S&P Global Sustainability Yearbook 2024
Sustainability | February 20, 2024

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose


GSK completes acquisition of Aiolos Bio
News | February 19, 2024

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody


Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
News | February 18, 2024

Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery